Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo
Molecular Therapy - Methods & Clinical Development · 2023-06 · 29 · 120-132
DOI: 10.1016/j.omtm.2023.02.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-06. Verfasst von Patrick C Freitag und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Clinical success in T cell therapy has stimulated widespread efforts to increase safety and potency and to extend this technology to solid tumors. Yet progress in cell therapy remains restricted by the limited payload capacity, specificity of target cell transduction, and transgenic gene expression efficiency of applied viral vectors. This renders complex reprogramming or direct in vivo applications difficult. Here, we developed a synergistic combination of trimeric adapter constructs enabling T cell-directed transduction by the human adenoviral vector serotype C5 in vitro and in vivo. Rationally chosen binding partners showed receptor-specific transduction of otherwise non-susceptible human T cells by exploiting activation stimuli. This platform remains compatible with high-capacity vectors for up to 37 kb DNA delivery, increasing payload capacity and safety because of the removal of all viral genes. Together, these findings provide a tool for targeted delivery of large payloads in T cells as a potential avenue to overcome current limitations of T cell therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- Cellular Immunotherapy, Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Zitieren
APA
Freitag, P. C., Kaulfuss, M., Flühler, L., Mietz, J., Weiss, F., Brücher, D., Kolibius, J., Hartmann, K. P., Smith, S. N., Münz, C., Chijioke, O., & Plückthun, A. (2023). Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo. Molecular Therapy - Methods & Clinical Development, 29, 120-132. https://doi.org/10.1016/j.omtm.2023.02.012
Vancouver
Freitag PC, Kaulfuss M, Flühler L, Mietz J, Weiss F, Brücher D, et al. Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo. Molecular Therapy - Methods & Clinical Development. 2023;29:120-132. doi:10.1016/j.omtm.2023.02.012
BibTeX
@article{Freitag2023,
author = {Freitag, Patrick C and Kaulfuss, Meike and Flühler, Lea and Mietz, Juliane and Weiss, Fabian and Brücher, Dominik and Kolibius, Jonas and Hartmann, K Patricia and Smith, Sheena N and Münz, Christian and Chijioke, Obinna and Plückthun, Andreas},
title = {Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {29},
pages = {120--132},
doi = {10.1016/j.omtm.2023.02.012}
}
EUVIMED